Tiziana Life Sciences (TILS) was last week’s AIM ramp, briefly touching 300p on Friday (a £506 million market cap) before closing for the weekend at 268p. It’s more than 10-bagged from its 24p low at the end of February and, as you might have guessed, the reason is because it’s a coronavirus ramp...
Hello Share Mates. Last week I commended a medical pioneer to your attention because it had just announced exciting news. The Nasdaq and AIM-listed Tiziana (TILS)was given an encouraging boost by the Harvard Medical School no less for a positive test for its Foralumab drug for boosting the immune system.
Hello Share Tramplers. In the spirit of support for small medical pioneers, hoping they’ll hit the jackpot one day, today’s choice has just had encouraging tidings. Tiziana Life Sciences (TILS) needs some better news, as it’s share price has dived over the last few years. So we are talking about a potential recovery play here...
Hello, Share Troopers. Previously, I’ve written on the huge potential of life science companies which explore antibodies and antibody substitutes in the fight against serious conditions. Allow me to put another such firm before you. Tiziana Life Sciences (TILS) is biotechnology outfit which uses antibodies to find new treatments for inflammatory diseases and cancers...
Hello, Share Schemers. Some of us have a warm feeling when we invest in a company which hopes to push back the onslaught of awful conditions like cancer. But it helps if the medical pioneer has a treatment under review which may have a good chance of working. So may I bring to your attention a company on both AIM and the Nasdaq...
While it is the case that for the FTSE 100 and many blue chips 2015 was a year to forget, further down the stock market there were some bright spots for which period January to December 2015 was a triumph from the get go.
Tiziana Life Science is a chart play of interest at the moment given the way the shares are clearly in the middle of a bull run of note.
